Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy ...

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration ...

Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce ...

Designed specifically for emerging biotechs, the Early Phase Center of Excellence brings together Avance Clinical’s scientific, regulatory, and operational experts to streamline first-in-human and ...

Moving Biotech receives US FDA’s IND clearance for 4P004; strengthens its position as a leading innovator in disease-modifying osteoarthritis therapeutics: Lille, France Saturd ...

The Board has released the schedule for class 10, 11, and 12 exams. Students can check exam dates and shift timings here.

Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt ...

Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming ...

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...